138 related articles for article (PubMed ID: 17260489)
1. Analysis of metastatic ovarian tumors from extragenital primary sites.
Turan T; Aykan B; Koc S; Boran N; Tulunay G; Karacay O; Erdogan Z; Kose F
Tumori; 2006; 92(6):491-5. PubMed ID: 17260489
[TBL] [Abstract][Full Text] [Related]
2. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
Poncelet C; Fauvet R; Yazbeck C; Coutant C; Darai E
Eur J Surg Oncol; 2010 Nov; 36(11):1066-72. PubMed ID: 20817462
[TBL] [Abstract][Full Text] [Related]
3. Preoperative diagnosis of metastatic ovarian cancer is related to origin of primary tumor.
Guerriero S; Alcazar JL; Pascual MA; Ajossa S; Olartecoechea B; Hereter L
Ultrasound Obstet Gynecol; 2012 May; 39(5):581-6. PubMed ID: 21998039
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical significance of tumor markers in ovarian mature cystic teratoma.
Chen JM; Gao HY; Wang Q; Li Q
Clin Exp Obstet Gynecol; 2016; 43(3):397-400. PubMed ID: 27328499
[TBL] [Abstract][Full Text] [Related]
5. Surgical Treatment of Metastatic Ovarian Tumors From Extragenital Primary Sites.
Sal V; Demirkiran F; Topuz S; Kahramanoglu I; Yalcin I; Bese T; Sozen H; Tokgozoglu N; Salihoglu Y; Turan H; Iyibozkurt C; Kolomuc T; Sofiyeva N; Berkman S; Arvas M
Int J Gynecol Cancer; 2016 May; 26(4):688-96. PubMed ID: 26937750
[TBL] [Abstract][Full Text] [Related]
6. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
7. Appendiceal mucinous neoplasm mimics ovarian tumors: Challenges for preoperative and intraoperative diagnosis and clinical implication.
Zhang W; Tan C; Xu M; Wu X
Eur J Surg Oncol; 2019 Nov; 45(11):2120-2125. PubMed ID: 31462390
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
9. Preoperative clinical and radiological features of metastatic ovarian tumors.
Bruchim I; Ben-Harim Z; Piura E; Tepper R; Fishman A
Arch Gynecol Obstet; 2013 Sep; 288(3):615-9. PubMed ID: 23471547
[TBL] [Abstract][Full Text] [Related]
10. [Role of Ca-125 in the differential diagnosis of adnexal mass in breast cancer patients].
Grabiec M; Nowicki P; Walentowicz M; Greźlikowska U; Mierzwa T; Chmielewska W
Ginekol Pol; 2005 May; 76(5):371-6. PubMed ID: 16145856
[TBL] [Abstract][Full Text] [Related]
11. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
[TBL] [Abstract][Full Text] [Related]
12. CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
Sagi-Dain L; Lavie O; Auslander R; Sagi S
Int J Biol Markers; 2015 Jul; 30(3):e333-40. PubMed ID: 25704505
[TBL] [Abstract][Full Text] [Related]
13. [Adnexal tumors after surgical treatment of colorectal cancer].
Gottwald L; Korczyński J; Góra E; Bieńkiewicz A
Ginekol Pol; 2008 Apr; 79(4):259-63. PubMed ID: 18592863
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
15. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics.
Antila R; Jalkanen J; Heikinheimo O
Gynecol Oncol; 2006 Apr; 101(1):97-101. PubMed ID: 16278010
[TBL] [Abstract][Full Text] [Related]
16. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
17. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
18. Difficulty in diagnosis and different prognoses between colorectal cancer with ovarian metastasis and advanced ovarian cancer: An empirical study of different surgical adoptions.
Lee KC; Lin H; ChangChien CC; Fu HC; Tsai CC; Wu CH; Ou YC
Taiwan J Obstet Gynecol; 2017 Feb; 56(1):62-67. PubMed ID: 28254228
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
Kim JH; Jun KH; Jung H; Park IS; Chin HM
Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
